100 related articles for article (PubMed ID: 19180065)
1. Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone.
Kushner RF; Sujak M
Obesity (Silver Spring); 2009 May; 17(5):1017-22. PubMed ID: 19180065
[TBL] [Abstract][Full Text] [Related]
2. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.
Smith SR; De Jonge L; Volaufova J; Li Y; Xie H; Bray GA
Metabolism; 2005 Jan; 54(1):24-32. PubMed ID: 15562376
[TBL] [Abstract][Full Text] [Related]
3. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes.
Shah PK; Mudaliar S; Chang AR; Aroda V; Andre M; Burke P; Henry RR
Diabetes Obes Metab; 2011 Jun; 13(6):505-10. PubMed ID: 21272186
[TBL] [Abstract][Full Text] [Related]
4. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.
Bray GA; Smith SR; Banerji MA; Tripathy D; Clement SC; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Musi N; Ratner RE; Schwenke DC; Stentz FB; Reaven PD; DeFronzo RA
Diabetes Obes Metab; 2013 Oct; 15(10):931-7. PubMed ID: 23551856
[TBL] [Abstract][Full Text] [Related]
5. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
6. Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes.
Lin KD; Lee MY; Feng CC; Chen BK; Yu ML; Shin SJ
Diabet Med; 2014 Nov; 31(11):1341-9. PubMed ID: 24797920
[TBL] [Abstract][Full Text] [Related]
7. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes.
Zib I; Jacob AN; Lingvay I; Salinas K; McGavock JM; Raskin P; Szczepaniak LS
J Investig Med; 2007 Jul; 55(5):230-6. PubMed ID: 17850734
[TBL] [Abstract][Full Text] [Related]
8. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
[TBL] [Abstract][Full Text] [Related]
9. The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypocaloric weight loss.
Shea MK; Nicklas BJ; Marsh AP; Houston DK; Miller GD; Isom S; Miller ME; Carr JJ; Lyles MF; Harris TB; Kritchevsky SB
Obesity (Silver Spring); 2011 Aug; 19(8):1636-46. PubMed ID: 21233810
[TBL] [Abstract][Full Text] [Related]
10. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.
Basu A; Jensen MD; McCann F; Mukhopadhyay D; Joyner MJ; Rizza RA
Diabetes Care; 2006 Mar; 29(3):510-4. PubMed ID: 16505497
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial.
Grey A; Beckley V; Doyle A; Fenwick S; Horne A; Gamble G; Bolland M
Eur J Endocrinol; 2012 Jun; 166(6):1087-91. PubMed ID: 22408124
[TBL] [Abstract][Full Text] [Related]
12. Effect of thiazolidinediones on body weight in patients with diabetes mellitus.
Fonseca V
Am J Med; 2003 Dec; 115 Suppl 8A():42S-48S. PubMed ID: 14678865
[TBL] [Abstract][Full Text] [Related]
13. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis.
Balas B; Belfort R; Harrison SA; Darland C; Finch J; Schenker S; Gastaldelli A; Cusi K
J Hepatol; 2007 Oct; 47(4):565-70. PubMed ID: 17560678
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
[TBL] [Abstract][Full Text] [Related]
16. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.
Hwang YC; Lee EY; Lee WJ; Cha BS; Yoon KH; Park KS; Lee MK
Metabolism; 2008 Apr; 57(4):479-87. PubMed ID: 18328348
[TBL] [Abstract][Full Text] [Related]
18. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.
Doehner W; Erdmann E; Cairns R; Clark AL; Dormandy JA; Ferrannini E; Anker SD
Int J Cardiol; 2012 Dec; 162(1):20-6. PubMed ID: 22037349
[TBL] [Abstract][Full Text] [Related]
19. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity.
Shadid S; Jensen MD
Diabetes Care; 2003 Nov; 26(11):3148-52. PubMed ID: 14578253
[TBL] [Abstract][Full Text] [Related]
20. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
